In addition, we showed that selinexor, a selective inhibitor of XPO1 that has been used as a pan-cancer agent in preclinical and phase I clinical trials [32, 33], effectively inhibits the growth of AML cells harboring the NPM1-fusions, as it does in NPM1c AML. This evidence concerns the gene NPM1 and acute myeloid leukemia.